Trials / Completed
CompletedNCT00659893
Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2
A Multi-center, Open Label, Dose-area Escalation, Cohort Study to Evaluate the Safety and Tolerability of 0.05% PEP005 Topical Gel Applied for Two Consecutive Days to Treatment Area(s) of up to a Total of 100 cm2 in Patients With Actinic Keratoses on the Extensor (Dorsal Aspect) Forearm(s)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Peplin · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study Hypothesis: Safety and Tolerability will differ when treating multiple contiguous 25 cm2 treatment areas, as compared to individual 25 cm2 treatment areas.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PEP005 Topical gel | 0.05%, two day dose |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2008-04-17
- Last updated
- 2015-09-14
Locations
13 sites across 2 countries: United States, Australia
Source: ClinicalTrials.gov record NCT00659893. Inclusion in this directory is not an endorsement.